Vermillion : Investor Overview

During the first phase, we expanded our leadership team by hiring new heads of sales and customer experience, managed markets, marketing, operations, a chief medical officer and a chief executive officer. In addition, we expanded our commercial strategy, reestablished medical and advisory support, rebuilt our patient advocacy strategy and established a billing system and a payer strategy outside of our relationship with Quest Diagnostics. During the second phase, we plan to obtain licensure of ASPiRA LABS in all 50 states, establish our own payer coverage for OVA1 (MIA) and launch a second-generation OVA1 test, known as Overa (MIA2G). In the third phase we plan to commercialize Overa (MIA2G) by utilizing the full national licensure of ASPiRA LABS, managed care coverage in select markets, our sales force and existing customer base. Unlike OVA1 (MIA), Overa (MIA2G) uses a global testing platform, which will allow Overa to be deployed internationally. We also plan to demonstrate proof of concept for a LDT product series, which we refer to internally as OvaX. We anticipate that OvaX will include not only biomarkers, but also clinical risk factors and patient history data in order to boost predictive value.

Vermillion, Inc. is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Vermillion, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vermillion, Inc. or its management. Vermillion, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

• Canaccord Genuity
• LifeSci Capital